AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$QTTB

Violette Shelia M. sold $8K of QTTB

Violette Shelia M. (Chief Scientific Officer) sold 917 shares of Q32 Bio Inc. (QTTB) at $8.32 on 2026-10-06.

Original reporting
SEC EDGAR · Violette Shelia M.
Published Oct 14, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$QTTB
Bearish
high confidence
Mentioned
$QTTB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTTBBearishLow
01

Why it matters

While the dollar amount is trivial, the sale by a senior scientific officer may be interpreted by investors as a mild negative signal.

02

Market read

The filing is a routine insider transaction with limited trading relevance; most traders will likely ignore it.

03

What to watch

Potential upcoming corporate events (e.g., trial data) that may have prompted the insider to liquidate a small position.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering transparency into insider sentiment.

Company-level read

Ticker impact

$QTTBBearishHigh confidence
Context

Chief Scientific Officer sold 917 shares for $7,629, a routine insider sale disclosed via Form 4.

Expected impact

modest downward pressure as market prices in the insider sale

Evidence & confidence

Small transaction size relative to float and low dollar amount suggests limited market impact, but sells by senior insiders are often viewed negatively.

Market effects

Sector

Minimal; biotech sector unlikely to be affected by a single small insider sale.

Regional

None; the filing is U.S. specific and does not influence broader regional markets.

Global

Insignificant; no global market impact expected.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing and not indicative of negative fundamentals.

Key entities

  • company
    Q32 Bio Inc.

    Biotech firm developing RNA‑based therapeutics, ticker QTTB.

  • person
    Violette Shelia M.

    Chief Scientific Officer of Q32 Bio who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

QTTB insider trading history →

Related articles

SEP 30
$QTTBHighAI 8/10

Why is Q32 Bio stock surging today?

Q32 Bio (QTTB) stock surged 20.8% in pre-market trading after releasing Phase 2a results for bempikibart at the EADV Congress. The data showed 36-week efficacy and 16-week off-drug findings for alopecia areata. Analysts initiated coverage with Buy ratings and price targets of $29 (Jefferies) and $38 (Clear Street), citing high revenue potential and favorable safety profile. The broader market had a mild positive impact.

investing.com2 min
SEP 30
$QTTBMedAI 8/10

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of…

Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 — Clinically meaningful efficacy data observed on primary and key secondary e

SEC EDGAR 8-K2 min
SEP 30
$QTTBHighAI 8/10

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio (QTTB) presented 36-week results from its SIGNAL-AA Phase 2a trial of bempikibart for alopecia areata at EADV 2026. The drug showed clinically meaningful efficacy, with a 35.3% mean reduction in SALT scores. 40% of patients achieved SALT-20 response. The 16-week off-drug period showed durable responses, with 44% maintaining SALT-20. Q32 Bio plans to advance a registration-directed program in 2027.

prnewswire.com2 min
SEP 14
$QTTBMedAI 8/10

Q32 Bio Appoints New CMO And CDO To Support Advancement Of Bempikibart

Q32 Bio Inc. (QTTB) appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company is advancing Bempikibart into late-stage development for alopecia areata, with a registration-directed program planned for 2027. Bempikibart showed promising results in early trials, including hair regrowth and a well-tolerated safety profile. QTTB's stock is currently trading at $11.14, up 0.39%.

rttnews.com2 min
SEP 5
$AAPLHighAI 8/10

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?

Apple (AAPL), Q32 Bio (QTTB), and CSX Corp. (CSX) reached 52-week highs. AAPL rose 0.6% to $323.45; Citi raised its target to $365. QTTB surged 90% after positive clinical data; Wells Fargo upgraded it to 'Overweight' with a $66 target. CSX gained 0.4% to $49.90; Raymond James lifted its target to $56. Year-to-date gains: AAPL +16%, CSX +36%, QTTB +543%.

stocktwits.com2 min